Assay development optimisation & technology

#Assay #Assay development optimisation & technology #Drug discovery #Research

BellBrook Labs given NIH funding for work on antitumour immunity 

Drug discovery company BellBrook Labs has been awarded a $300,000 Phase I Small Business Innovative Research grant to develop and validate HTS assays for the discovery of small-molecule antagonists of TREX1. Immunotherapy approaches such as immune checkpoint blockade are said to be transforming oncology. However, many patients do not respond to… Read More

#News

#Assay development optimisation & technology #Covid-19 #Immunology / Virology & Vaccines

Bio-Rad launches new SARS-CoV-2 serology assay panel

Bio-Rad’s Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel is a ready-to-use, qualitative multiplex immunoassay panel which has been designed to provide quick, precise detection of IgG antibodies against four SARS-CoV-2 antigens. This “provides useful information about natural exposure rates in a population or about vaccine immunogenicity,” said Candice Cox,… Read More

#Covid-19 #News

#Assay development optimisation & technology #Online focus

Extending sensitivity of biomarker quantitation immunoassays

Patricia Ahrweiler, Field Marketing Manager, Gyros Protein Technologies explains how its Gyrolab Bioaffy 4000 CD extends Gyrolab assay sensitivity to the low picogram level for improved analysis of biomarkers Biomarker research has accelerated in recent years, driving the development of novel biomarker candidates and panels for the study of… Read More

#Exclusive Content #News

#AI #Assay development optimisation & technology #Biologics / Biotechnology #Cancer research #Drug development #Drug discovery #Vaccines

Latest issue of DDW now available

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Drug development #Drug discovery #Narrated podcasts #Research

Innovation and Opportunity in Drug Discovery

Today’s episode on the topic of Innovation and Opportunity in Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Japanese drug development: Where is the innovation, Where are the opportunities in global drug discovery, and New for Old: The value behind drug repurposing. These… Read More

#Podcasts

#Assay development optimisation & technology

Precision control of protein release to reconfigure bioprocessing

Dr J. Mark Treherne, Dr Christian Pernstich and Dr Michael Jones examine how the controlled release of proteins will  improve the reproducibility of cell-based drug discovery screens? Cell-based screening systems are now routinely incorporated as pivotal decision-making assays much earlier into the drug discovery process across most therapeutic areas and… Read More

#Editor's Choice #Exclusive Content #News

#Antibody #Assay development optimisation & technology

LSBIO acquires Absolute Antibody

LSBio, a provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody, its sister company Kerafast. LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The company has built a catalogue of more than 750,000 reagent antibodies, assay kits,… Read More

#News #Trending News

#Assay development optimisation & technology #Drug discovery

Why kinetic assays are important to drug discovery

In this free webinar, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience will provide exclusive insight into the importance of kinetic assays in the drug discovery process. Viewers will gain knowledge on kinetic assay design and how to design assays that deliver hits with higher physiological relevance. Putting the dynamics… Read More

#Editor's Choice #News

#Assay development optimisation & technology #Drug discovery #High Content Screening #RNA

PerkinElmer to acquire Horizon Discovery for $383 million

PerkinElmer will acquire Horizon Discovery for approximately $383 million (£296 million). The transaction is expected to close in the first quarter of 2021 subject to conditions. The investment will allow PerkinElmer to expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and… Read More

#News #Trending News

#Assay development optimisation & technology #Covid-19 #Therapeutics

PerkinElmer immunoassay helps identify therapeutic compounds to tackle COVID-19

A research team at the National Center for Advancing Translational Sciences (NCATS), an arm of the National Institutes of Health (NIH), is working with PerkinElmer’s AlphaLISA immunoassay to help support the global search for effective COVID-19 therapeutics. The NCATS research project is focused on studying small molecule drug compounds that… Read More

#Covid-19 #News

#Assay development optimisation & technology #Corning Life Sciences #Tissue chips

Why we should be interested in human tissue chips

Dr. Kacey Ronaldson-Bouchard (pictured) explains why adapting cell-based assays from suspension cells to 2D culture, 3D culture, and beyond to ‘patient in a dish’ systems is not an exercise undertaken lightly. However, the effort pays off on many levels.  Our incomplete understanding of human biology and the limited potential for human… Read More

#Exclusive Content

#Assay development optimisation & technology #BioDot #PCR

Considerations for scaling assays in life science

As the demand for assay data continues to grow and enabling technology allows us to generate huge datasets at impressive speeds, assay design is as critical as ever says Brian, Kirk, Vice President, Business Development, BioDot. While assay scaling has obvious benefits with respect to data analysis and providing answers… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

High content screening in action: a powerful tool to identify novel antivirals and vaccines

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Organic chemistry #Pharmokinetics #Precision medicine #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The COVID-19 antiviral race: we’re all in this together

The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Clinical specialities #Drug development #Enabling technologies #Flow Cytometry #Genetics / genomes #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead optimisation #Microfluidics #PCR #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Toxicology

Creating vaccines drop by drop

By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways,… Read More

#Covid-19 #Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The CELL CULTURE innovations increasing drug discovery success

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development… Read More

#Exclusive Content